Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
KAMADA LTD director Karnit Goldwasser reported three employee stock option awards dated August 27, 2026, held by a trustee under the company’s 2011 Share Award Plan. The awards cover 26,500 ordinary shares at a $7.41 exercise price, 30,000 at $5.99, and 30,000 at $7.38. The exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026, and are presented in USD using the September 22, 2026 NIS/USD exchange rate.
KAMADA LTD reported indirect acquisitions of employee stock options covering 15,000 and 60,000 ordinary shares in transactions reported for VP Plasma Operations Beladev Shavit on August 27, 2026. The options are held by a trustee under the company’s 2011 Share Award Plan. Their exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026, with a record date of August 27, 2026. The options are denominated in NIS, with exercise prices presented in USD as $5.98 and $7.44. No Rule 10b5-1 plan is reported.
Nir Livneh, Kamada's VP, General Counsel, reported two indirect employee stock option awards held by a trustee under the company's 2011 Share Award Plan on August 27, 2026: 29,485 options at a $5.43 exercise price and 60,000 options at $7.44. The reported USD exercise prices were adjusted in connection with a special cash dividend. The options vest in four equal installments, with 25% vesting on each anniversary of the grant date. No Rule 10b5-1 plan is reported.
KAMADA LTD (KMDA) reported two employee stock-option awards associated with Orit Pinchuk, VP Regulatory Affairs, dated August 27, 2026, covering 15,000 and 60,000 ordinary shares. The options are held by a trustee under the Company's 2011 Share Award Plan, with exercise prices of $5.98 and $7.44 per share, respectively. The prices were adjusted in connection with a special cash dividend declared August 17, 2026, with a record date of August 27, 2026. Options vest in four equal installments, 25% on each grant-date anniversary. No Rule 10b5-1 plan is reported.
KAMADA LTD director Leon Recanati reported three employee stock option awards dated August 27, 2026, held by a trustee under the company’s 2011 Share Award Plan. The options cover 26,500, 30,000 and 30,000 ordinary shares, with exercise prices of $7.41, $5.99 and $7.38, respectively. They vest over four years in four equal installments, with 25% vesting on each anniversary, and are exercisable for 10 years after grant. The listed exercise prices are presented in U.S. dollars using the Bank of Israel NIS/USD exchange rate as of September 22, 2026.
Orlev Chaime, KAMADA LTD (KMDA)'s Chief Financial Officer, reported three employee stock option awards on August 27, 2026, held by a trustee under the Company's 2011 Share Award Plan. The awards cover 22,500, 90,000 and 90,000 ordinary shares, with respective exercise prices adjusted to $5.98, $6.02 and $7.44 in connection with a special cash dividend. No Rule 10b5-1 plan is reported.
KAMADA LTD VP, Operations Nir Eran reported two employee stock option awards on August 27, 2026: 22,500 options at a $5.98 exercise price and 90,000 options at a $7.44 exercise price. Both are held by a trustee under the company's 2011 Share Award Plan and vest in four equal installments, with 25% vesting on each grant anniversary. The exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026, with a record date of August 27, 2026. The prices are presented in U.S. dollars based on the Bank of Israel exchange rate as of September 22, 2026; no Rule 10b5-1 plan is reported.
KAMADA LTD (KMDA) director Assaf Itshayek reported two indirect employee stock option acquisitions dated August 27, 2026, held by a trustee under the company’s 2011 Share Award Plan. The options cover 16,000 ordinary shares at a $6.10 exercise price and 30,000 at $7.38. The exercise prices were adjusted from $6.27 and $7.55, respectively, in connection with a special cash dividend declared August 17, 2026, with an August 27, 2026 record date.
The options vest over four years in four equal installments, with 25% vesting on each grant anniversary, and are exercisable for 10 years following grant; unexercised options expire immediately thereafter. Exercise prices are presented in U.S. dollars based on the Bank of Israel NIS/USD exchange rate as of September 22, 2026.
KAMADA LTD director Dekel Benjamin reported two employee stock-option awards on August 27, 2026, held by a trustee under the company's 2011 Share Award Plan: one covering 16,000 ordinary shares at a $6.10 exercise price and another covering 30,000 ordinary shares at $7.38. The exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026, with an August 27, 2026 record date. The options vest over four years in four equal installments and are exercisable for 10 years following the grant date. No Rule 10b5-1 plan is reported.
KAMADA LTD’s VP, Marketing & Sales, Neheman Hanni, reported two indirect employee stock option awards on August 27, 2026, held by a trustee under the company’s 2011 Share Award Plan: options covering 15,000 and 60,000 ordinary shares. Their adjusted exercise prices are $5.98 and $7.44 per share, respectively, in connection with a special cash dividend declared August 17, 2026. Each award vests in four equal installments, with 25% vesting on each of the four anniversaries of its grant date.